Home/Filings/4/0001818382-25-000113
4//SEC Filing

Niklason Laura E 4

Accession 0001818382-25-000113

CIK 0001818382other

Filed

Jun 15, 8:00 PM ET

Accepted

Jun 16, 4:31 PM ET

Size

8.8 KB

Accession

0001818382-25-000113

Insider Transaction Report

Form 4
Period: 2025-06-12
Niklason Laura E
DirectorPresident, CEO and Director
Transactions
  • Award

    Stock Options (right to buy)

    2025-06-12+00 total(indirect: By Spouse)
    Exercise: $2.41Exp: 2035-06-12Common Stock (80,000 underlying)
Holdings
  • Common Stock

    243,851
  • Common Stock

    (indirect: By LLC)
    2,241,045
  • Common Stock

    (indirect: By Trust)
    1,148,240
  • Common Stock

    (indirect: By Spouse)
    0
Footnotes (2)
  • [F1]This Form 4 amends the previously reported number of shares owned by Brady W. Dougan and Ayabudge LLC, an entity controlled by Brady W. Dougan, to correct an error in a Form 4 filed by the Reporting Person on August 21, 2023 (the "Original Form 4"). The Original Form 4 reported the sale of 510,161 shares of common stock of Humacyte, Inc. as a sale by Ayabudge LLC; however, these shares were sold by Mr. Dougan.
  • [F2]The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029.

Issuer

Humacyte, Inc.

CIK 0001818382

Entity typeother

Related Parties

1
  • filerCIK 0001878075

Filing Metadata

Form type
4
Filed
Jun 15, 8:00 PM ET
Accepted
Jun 16, 4:31 PM ET
Size
8.8 KB